Protocol No.: M25-709

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA)
Principal Investigator
Pfaendler, Krista
Phase
II
Age Group
Adult
Applicable Disease Site
Gynecologic Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Jill Stone, LPN
Research Specialist
Phone: +1 304-634-4417

View on ClinicalTrials.gov